Heartflow's AI Plaque Analysis software leads to significant improvements in cholesterol management and cardiac risk reduction in coronary artery disease patients.
Key Details
- 1DECIDE Registry, the largest prospective study of its kind, enrolled ~20,000 CAD patients at 30+ US clinical sites.
- 2Heartflow AI Plaque Analysis prompted treatment changes in over 50% of patients versus CCTA alone.
- 3Patients managed using the software saw mean LDL cholesterol reductions of 18.7 mg/dL.
- 4A 15% estimated reduction in cardiac event risk was observed for these patients.
- 5Significant management changes occurred even in patients with no calcified plaque.
- 6The AI provides individualized risk insights by quantifying and characterizing all plaque types, including non-calcified, soft plaques.
Why It Matters
This large-scale prospective evidence demonstrates that adding AI-based plaque quantification to CCTA can materially change patient management, with potential to reduce adverse cardiac events. These results highlight the growing role of imaging AI in personalizing cardiovascular care.
Source
Cardiovascular Business
Related News
•Cardiovascular Business
Radiology Leads in FDA-Cleared Imaging AI Algorithms, Cardiology Surges
Radiology maintains its lead as the specialty with the most FDA-cleared AI algorithms, while cardiology now surpasses 200 cleared tools.
•AuntMinnie
Deep Learning CT Muscle Segmentation Enhances Sarcopenia Detection in COPD
A deep learning model for CT-based 3D pectoralis muscle segmentation outperforms standard 2D techniques in assessing muscle loss among COPD patients.
•AuntMinnie
Stanford Launches Merlin: 3D AI Model for Abdominal CT Interpretation
Stanford researchers introduce Merlin, a 3D vision-language AI model for interpreting abdominal CT scans, demonstrating strong performance across multiple radiology tasks.